« Return to News | Awards & Advancement

Vince & Associates Clinical Research expands

Thursday, April 21, 2011 12:33 PM

Kansas-based Vince & Associates Clinical Research, a provider of phase I-IV clinical trial services to the global biopharmaceutical industry, has opened a 90-bed clinical pharmacology research unit.

The design delivers a hotel-type experience for the study volunteers and a scientific research setting for the biopharmaceutical industry. Bedside 20-inch touch screen entertainment systems, in-house theater room, and individually themed suites are some of the amenities for the study volunteers. 

“We provide full technical resources for phase I/IIa Proof of Concept (POC) studies which incorporate a single ascending dose (SAD), multiple ascending dose (MAD) and a patient proof of concept study into a single protocol.”

Vince and Associates has also invested in facilities such as a USP 797-compliant Biosafety cabinet and full time pharmacy staff. This investment allows for sterile preparation from client’s API to be compounded on site as well as full capability to prepare drug extemporaneously, a common requirement for these early clinical trials.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.